bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 4632: Decitabine for neuroblastoma cure: Target therapy induced ongoing acquisition of RD3 loss and reverts tumor evolution
Authors: Natarajan Aravindan , Somasundaram Dinesh Babu , Aravindan Sheeja , Natarajan Mohan , Herman Terence 
Published: August 2018

Abstract
Recently, we defined the novel tumor evolution stabilization role of Retinal degeneration protein 3 (RD3), regulating the metastatic state of neuroblastoma (NB) cells in vitro and their metastatic potential in vivo. Our earlier studies in various tumor models recognized the role of therapy resistant residual cells in tumor recurrence and relapse. Herein, we investigated the ongoing acquisition of RD3 transcriptional regulation in radiotherapy surviving NB cells and further identified the potential drug candidates that can reprogram and reinstate RD3 transcription in these cells. Human NB (SH-SY5Y, SK-N-AS) cells exposed to single dose (10, 20, 50cGY, 1, 2, 4Gy) or fractionated (FIR, 2Gy/Day for 5 days) irradiation resulted in significant transcriptional repression of RD3. Drug screening with a panel of drugs that are in current clinical use, those in pipelines or in developmental stages by exposing radioresistant cells identified many potential drug candidates that could effectively restore RD3 transcription in this setting. Evidently, we found RD3 promoter region hypermethylation drives its transcriptional regulation in therapy resistant cells. To that note, FDA approved hypomethylating agent decitabine significantly reinforced RD3 transcription in this setting and further promoted cellular differentiation and completely inhibited the formation of organized tumorosphere under stem-cell culture conditions. Together, these results demonstrate the ongoing acquisition of RD3 loss in therapy resistant cells and further recognized the mechanism of how RD3 is regulated in this setting. More importantly, this results of this study identified a drug candidate, that has been already in clinical use, that could be beneficial in mitigating therapy resistance and better clinical outcomes for the patients presented with high-risk advanced disease. Funding: NIH-COBRE-IP20GM103639-01, OUHSC-COM-Radiation Oncology Research Development Funds
Citation Format: Aravindan Natarajan, Dinesh Babu Somasundaram, Sheeja Aravindan, Mohan Natarajan, Terence Herman. Decitabine for neuroblastoma cure: Target therapy induced ongoing acquisition of RD3 loss and reverts tumor evolution [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4632.
Abstract 4665: Neurotensin receptor-based targeted delivery of thymoquinone for non-small cell lung cancer
Authors: Singh Santosh Kumar , Lillard James W. , Singh Rajesh 
Published: August 2018

Abstract
Non-small cell lung cancer (NSCLC) is a very recalcitrant cancer, accounting for 80% to 85% of all lung cancer diagnoses. About 40% of NSCLC are adenocarcinomas. Thus, there is an urgent need to identify targeted therapies, specifically for NSCLC. Although, multiple signaling molecules have now been identified within the last decade, among them Neurotensin receptor 1 (NTSR1) have afforded an improved understanding of the underlying pathology and significant heterogeneity of NSCLC. NTSR1 belongs to the G-protein coupled receptors (GPCR) superfamily that has been shown numerous oncogenic effects in tumor initiation, progression, proliferation, apoptosis, and metastasis. In the present study, we used a novel method for targeted delivery of Thymoquinone (TQ), a constituent of Nigella sativa at the desired location. We described a proprietary planetary ball milling (PBM) approach that uses a natural polysaccharide (starch; FDA approved) to create a drug-polysaccharide nanoparticle as a core that is subsequently coated with poly (ϵ-caprolactone) / poly (ethylene glycol) copolymer and conjugated with anti-NTSR1-mAb, which allows binding to high-affinity NTSR1 receptors presents on NSCLC. Our tissue microarray data show higher expression of NTSR1 in lung cancer patients, which were negligible in normal cells. These studies were further confirmed by targeting NTSR1 in lung cancer cell lines NCI-H1563, NCI-H1975 and MRC-5 using our novel anti-NTSR1 conjugated, and TQ encapsulated PBM nanoparticle and further, validated using flow cytometry, immunofluorescence, qRT-PCR and western blot techniques. Our result showed the PBM nanoparticles encapsulated with TQ rapidly internalized and depolymerized the microtubule network by inducing apoptosis. The up-regulation of pro-apoptotic (BAX, BID) and down-regulation of anti-apoptotic (BCL-2, MCL-1) makers to confirm the targeted delivery of PBM-NPs to the tumor cells. This study strongly suggests anti-NTSR1-mAb conjugated PBM-NPs has its application to drugs targeting for the treatment of NSCLC. In summary, this study combines innovative ideas with an innovative technology to create new therapeutics and a new strategy to improve the treatment of NSCLC and has the potential to create a new class of targeted treatments for advanced lung cancer.
Citation Format: Santosh Kumar Singh, James W. Lillard, Rajesh Singh. Neurotensin receptor-based targeted delivery of thymoquinone for non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4665.
Abstract 4667: The use of fragment-based screening approaches to improve the specificity of inhibitors targeting malignant melanoma
Authors: Mukherjee Sreya , Spriggs Shardell , Wilder Paul , Yu Wenbo , Varney Kristen , MacKerell Alexander D. , Weber David J. 
Published: August 2018

Abstract
S100B belongs to the S100 protein family of Ca2+-binding proteins. Prior studies have shown that S100B is a biological marker for malignant melanoma. Increases in S100B levels are predictive of disease progression, recurrence, and overall low survival in the patients. It was shown previously that S100B binds to p53 and down-regulates its tumor suppression activities including growth arrest and apoptosis. Chemical biology and structure-based drug design methods are underway to inhibit S100B and restore p53 function. However, highly specific S100B inhibitors are required, so S100B can be blocked in melanoma without impairing S100A1 function in skeletal and cardiac muscle. With this goal in mind, a fragment-based screening approach using NMR and computational approaches is being applied. Results to date indicate that these methods can be used to identify specific small molecule fragments that target S100B and not S100A1. The fragments that uniquely bind S100B will then be considered with structural data of existing S100B-SBiX complexes to improve their specificity for binding S100B (i.e. versus S100A1). The inhibitor design strategy will also include improving the stability of the compounds their cell permeability, and their overall drug-like properties. The most promising of these new inhibitors will ultimately be used to target high levels of S100B found in malignant and rescue p53-dependent tumor suppression pathways in vivo with the goal of them having therapeutic value for treating malignant melanoma.
Citation Format: Sreya Mukherjee, Shardell Spriggs, Paul Wilder, Wenbo Yu, Kristen Varney, Alexander D. MacKerell, David J. Weber. The use of fragment-based screening approaches to improve the specificity of inhibitors targeting malignant melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4667.
Abstract 4673: Selective delivery of tumor specific antigen to dendritic cells by mannose-labeled PLGA nanoparticles to induce immune response for cancer immunotherapy
Authors: Byeon Yeongseon , Won Ji Eun , Kim Ga Hee , Kim Min Gi , Park Yeong Min , HAN Hee Dong 
Published: August 2018

Abstract
Objective: To overcome limitation of ex vivo manipulation against dendritic cells (DC) vaccines, we developed mannose-labeled poly(d,l-lactide-co-glycolide) nanoparticles (MN-PLGA-NPs). The MN-PLGA-NPs enabled selective delivery of tumor-specific antigen to mannose receptor overexpressed DCs without ex vivo manipulation.
Methods: Conjugation of mannose (MN) and polyvinyl alcohol (PVA) was analyzed by H-NMR. Size and zeta potential of the MN-PLGA-NPs were examined by dynamic light scattering using an electrophoretic light scattering photometer. Selective delivery efficiency of MN-PLGA-NPs to DCs was examined by confocal microscope and flow cytometry. Migration of DCs containing MN-PLGA-NPs was assessed flow cytometry. Therapeutic efficacy of MN-PLGA(OVA+poly I:C)-NPs was examined in EG7 tumor-bearing mouse models. Biological effect and activated CD8+ T cells in tumor tissue were confirmed by immunohistochemistry assay.
Results: Conjugation of MN and PVA was confirmed that the peaks for the CH2 of methylene group in PVA was observed at 1.48 ppm and 1.59 ppm, and CH of tetrahydropyran group in MN was observed at 3.40 ppm, 3.49 ppm, 3.76 ppm, and 5.41 ppm. Size and zeta potential of MN-PLGA-NPs were 200 nm formed spherical shape and -10 mV, respectively. Loading efficiency of OVA or poly I:C into MN-PLGA-NPs was 90 % or 45 %, individually. Intracellular uptake of MN-PLGA-NPs in DCs was increased through selective binding between MN and MN-receptor compared to PLGA-NPs. Additionally, DCs containing MN-PLGA-NPs exhibited efficient migration to popliteal lymph node.
Therapeutic efficacy of MN-PLGA-NPs showed significant inhibition of tumor growth in EG7 tumor-bearing mice compared to the control (p &lt; 0.001) and PLGA-NPs (p &lt; 0.05), and showed 100% of survival up to 60 days. Additionally, MN-PLGA-NPs treatment group showed a greater number of activated CD8+ T cells in tumor tissue compared to the other groups (p &lt; 0.001), and prevention effect of tumor growth resulted in effectively suppressed compared to the control (p &lt; 0.001) or PLGA-NPs (p &lt; 0.001).
Conclusion: MN-PLGA-NPs is an attractive system that can directly activate DC in vivo without ex vivo manipulation, which overcome the limitation of existing DC vaccine.
Keyword: dendritic cells, selective delivery, PLGA nanoparticle, cancer immunotherapy.
Citation Format: Yeongseon Byeon, Ji Eun Won, Ga Hee Kim, Min Gi Kim, Yeong Min Park, Hee Dong HAN. Selective delivery of tumor specific antigen to dendritic cells by mannose-labeled PLGA nanoparticles to induce immune response for cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4673.
Abstract 4675: B-cell and T-cell repertoire sequencing enables somatic hypermutation and minimal residual disease assessment
Authors: Song Chen , Liu Pingfang , Barry Andrew , Dimalanta Eileen T. , Stewart Fiona J. , Russello Salvatore , Davis Theodore B. 
Published: August 2018

Abstract
The study of complex immunological diseases has progressed through recent developments that enable the sequencing of the immune repertoire. Using this approach, the interrogation of disease progression is facilitated through analysis of millions of V(D)J combinations from both B-cell antibodies and T-cell Receptors (TCR). One major challenge of immune repertoire sequencing is to capture the structural and sequence complexities of antibody and TCR genes. We have developed and optimized a method for accurate sequencing of full-length immune gene repertoires of B-cells and T-cells. RNA extracted from PBMCs were used to generate immune sequencing libraries in duplicate from a single patient. Using a unique barcoding scheme specifically designed to discretely barcode each mRNA molecule with a unique molecule index (UMI), PCR copies of each mRNA fragment can be collapsed into a single consensus sequence, improving accuracy through the resolution of PCR bias and sequencing errors. Utilization of the UMIs enabled absolute quantification of input RNA molecules and accurate ranking of the antibody/TCR clone abundance. This approach was also applied to the analysis of tumor samples for abundance of expanded clones through clustering based on V gene, J gene and CDR3 similarity and ranking by mRNA abundance. The use of isotype-specific primers (IgM, IgD, IgG, IgA and IgE) enabled measurement of the heavy chain isotype proportions within the samples. Full-length heavy chain antibody sequences generated using this method were aligned to germline genes from reference databases, enabling quantitation of the mutation level of each antibody sequence, providing information on the overall maturity and mutational profile of the sample repertoire. Additionally, this approach was capable of detecting minimal residual diseases by sensitive quantification of TCR rearrangement. This novel method allows for exhaustive somatic mutation profiling across complete V, D and J segments and full isotype information analysis. The information obtained enables the possibility for synthesis and expression of complete antibody chains and T-cell receptor chains for downstream immunological assays.
Citation Format: Chen Song, Pingfang Liu, Andrew Barry, Eileen T. Dimalanta, Fiona J. Stewart, Salvatore Russello, Theodore B. Davis. B-cell and T-cell repertoire sequencing enables somatic hypermutation and minimal residual disease assessment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4675.
Abstract 4678: High-throughput single-cell linking of antigen specificities with T cell receptor sequences using de novo generated DNA-linked MHC tetramers
Authors: Jiang Ning , Zhang Shu-qi , He Chenfeng , Sun Eric , Zhang Mingliang , Jia Weiping 
Published: August 2018

Abstract
Identification of correlated antigens recognized by T cell and its T cell receptor (TCR) sequences at single cell level is extremely useful to the understanding and treating immune-related diseases. Although mass cytometry, CyTOF, has pushed the number of antigenic peptides that can be interrogated at once to around 100, the destructive nature of CyTOF prohibits linking pMHCs recognized by a T cell with its TCR receptor sequences. In addition, the high cost associated with peptide synthesis process prevents the quick generation of a peptide library that can be tailored to any pathogens or diseases. Here we describe a new technology, TetATCR-Seq for Tetramer Associated TCR sequencing, that is capable of de novo generating a large amount of peptides and mapping antigen recognition with single cell TCR sequences by DNA barcoded tetramers. It evolves three major steps: 1) de novo peptide generation, 2) DNA barcoded tetramer generation, and 3) single cell sequencing of tetramer DNA barcode and TCR sequences. By spiking in 5 altered peptide ligands (APL) that are known to bind to a HCV T cell clone with other 90 irrelevant peptides, we showed that the binding of all these 5 APLs can be faithfully detected by sequencing while non-specific binding is minimum. Using a published set of cancer neo-antigen sequences, we showed that these peptides and their wild type counterparts can be quickly generated. Resulted tetramers can be used to clearly identify a population of neo-antigen only or wild type antigen only or double positive T cells. Subsequent single cell TCR sequencing showed that TCR paired α and β chain sequences can be obtained in more than 80% of single sorted T cells. Simultaneous tetramer DNA barcode sequencing showed that many T cells are found to cross-reactive to both neo-antigen and its wild type counterpart, suggesting the necessity of strict screening for neo-antigen only TCR in adoptive cell transfer therapy. In summary, the TetaTCR-seq tool we developed here enables one to quickly survey antigen repertoire again TCR repertoire at single cell level for a large number of peptides. This is an extremely useful tool in profiling T cell repertoire reactivity in infection and vaccination. It is also a useful tool to screen for T cell cross-reactivity and select neo-antigen specific TCR for cancer immunotherapy.
Citation Format: Ning Jiang, Shu-qi Zhang, Chenfeng He, Eric Sun, Mingliang Zhang, Weiping Jia. High-throughput single-cell linking of antigen specificities with T cell receptor sequences using de novo generated DNA-linked MHC tetramers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4678.
Abstract 4692: High density of cytotoxic and regulatory T-lymphocytes in gastric cancers with microsatellite instability
Authors: Kim Hyoung-Il , Shin Su-Jin , Kim Sang Yong , Choi Yoon Young , Son Taeil , Cheong Jae-Ho , Hyung Woo Jin , Noh Sung Hoon 
Published: August 2018

Abstract
Introduction: MSI-high (MSI-H) colorectal cancer is known to be associated with increased tumor-infiltrating lymphocytes (TILs) and good prognosis. In gastric cancer, however, MSI status has rarely been evaluated in accordance with TILs. The objectives of our study were to clarify the relationships between MSI status and antitumor host immune response and to identify the impact of these factors on the prognosis of gastric cancer.
Methods: We evaluated 345 patients with gastric cancer who underwent gastrectomy with MSI typing. The numbers of TILs in tumor center was counted after immunohistochemical staining with anti-CD3, CD4, CD8, Foxp3, and granzyme B to quantify the subset of TILs. To evaluate systemic immune response, differential white blood cell count and prognostic nutritional index (PNI) were obtained.
Results: Of the 345 patients, 57 were MSI-H and 288 were non-MSI-H groups. MSI-H tumors carried significantly higher numbers of CD8+ T-cells, Foxp3+ T-cells, GZB+ T cells and higher ratio of Foxp3/CD4 and GZB/CD8. The prognostic effect of TILs was different in MSI-H and non-MSI-H groups. All subsets of TILs were not significant prognostic factor for recurrent-free survival (RFS) and overall survival (OS) in MSI-H group. However, in non-MSI-H group, multivariate analysis showed that stage, PNI and CD4+ T cells was independent prognostic factor for RFS; on the other hand, stage, PNI and ratio of Foxp3/CD4 was independent prognostic factor for OS.
Conclusions: The number of subset of TILs and the prognostic influence of systemic and local immune response were different between MSI-H and non-MSI-H tumors. The immunogenicity caused by microsatellite instability and subsequent host immune response is associated with cancer progression and patient prognosis of gastric cancer.
Citation Format: Hyoung-Il Kim, Su-Jin Shin, Sang Yong Kim, Yoon Young Choi, Taeil Son, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh. High density of cytotoxic and regulatory T-lymphocytes in gastric cancers with microsatellite instability [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4692.
Abstract 4695: Murine tumor growth suppression through CD8+CTLs via activated DEC-205+dendritic cells by sequential administration of α-galactosylceramide in vivo
Authors: Kogo Hideki , Takahashi Hidemi , Uchida Eiji 
Published: August 2018

Abstract
Cancer immunotherapy is mediated by the effective priming and activation of tumor-specific class I major histocompatibility complex molecule-restricted CD8+ cytotoxic T lymphocytes. DEC-205+ dendritic cells can cross-present the epitopes of captured tumor antigens associated with class I MHC molecules alongside co-stimulatory molecules to prime and activate tumor-specific CD8+ CTLs. Immunosuppressive tolerogenic DCs with reduced co-stimulatory molecules may be a cause of insufficient CTL induction. Hepa1-6-1 cells were established from the mouse hepatoma cell line Hepa1-6; these cells grow continuously after subcutaneous implantation into syngeneic C57BL/6 mice and do not prime CD8+ CTLs. Here, we show that the growing of tumors was suppressed by activated CD8+ CTLs with tumor-specific cytotoxicity through the administration of the glycolipid α-galactosylceramide, which is a compound known to stimulate invariant natural killer T cells and selectively activate DEC-205+ DCs. Moreover, we demonstrated that sequential repetitive intraperitoneal inoculation of α-GalCer every 48 hour appeared to convert tolerogenic DEC-205+ DCs into immunogenic DCs with a higher expression of co-stimulatory molecules and a greater cross-presentation capacity, which primed CTL precursors and induced tumor-specific CD8+ CTLs within the tumor environment without activating iNKT cells. These findings provide a new basis for cancer immunotherapy to convert tolerogenic DEC-205+ DCs within tumors into immunogenic DCs via the sequential administration of an immuno-potent lipid/glycolipid, and activated immunogenic DCs expressing sufficient suitable co-stimulatory molecules will prime and activate tumor-specific CD8+ CTLs within the tumor to control tumor growing.
Citation Format: Hideki Kogo, Hidemi Takahashi, Eiji Uchida. Murine tumor growth suppression through CD8+CTLs via activated DEC-205+dendritic cells by sequential administration of α-galactosylceramide in vivo [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4695.
Abstract 4705: The novel oncolytic peptide, DTT-304, induces regression of colorectal cancer tumors in vivo
Authors: Fleten Karianne G. , Eksteen Johannes J. , Mauseth Brynjar , Camilio Ketil , Rekdal Øystein , Wang Meng Yu , Mælandsmo Gunhild M. , Flatmark Kjersti 
Published: August 2018

Abstract
Colorectal cancer (CRC) is the third most common cancer in the world, and approximately 50% of the patients develop liver metastasis, which is a major cause of disease mortality. New drugs and treatment options are therefore necessary to improve the survival of these patients. Lately, different types of immunotherapy, such as check point inhibitors, have shown great promise in the treatment of metastatic cancer, although for most patients with CRC the efficacy has been restricted to cases with microsatellite instable disease. Another novel immunotherapeutic strategy is oncolytic immunotherapy, which has been shown to cause immunogenic cancer cell death. Following cancer cell lysis, damage associated molecular patterns (DAMPs) are released, which are recognized by immune cell receptors. Pro-inflammatory responses will then be triggered to induce release of tumor specific antigens that are presented to the immune system, leading to tumor-specific immune responses.
In the present study, we have investigated the efficacy of a novel oncolytic peptide, DTT-304, using two mouse models. Subcutaneous tumors were established in Balb c mice using the cell line CT26 and in C57Bl6 mice using the cell line MC38, both murine CRC cell lines. In both models, intra-tumoral injection of the peptide induced tumor necrosis and complete regression a few days after initiation of treatment, thus showing the potential of this peptide for use in colorectal cancer.
In ongoing experiments we are investigating if the peptide has the potential to induce long lasting protective tumor-specific immune responses by re-challenging previously treated mice with the same cell line in a liver metastasis model. In addition, the possibility of treating liver tumors by direct peptide injection will be investigated.
Citation Format: Karianne G. Fleten, Johannes J. Eksteen, Brynjar Mauseth, Ketil Camilio, Øystein Rekdal, Meng Yu Wang, Gunhild M. Mælandsmo, Kjersti Flatmark. The novel oncolytic peptide, DTT-304, induces regression of colorectal cancer tumors in vivo [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4705.